专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08198407B1 Sequential protein isolation and purification schemes by affinity chromatography 有权
标题翻译：通过亲和层析进行顺序蛋白质分离和纯化方案
公开(公告)号：US08198407B1
公开(公告)日：2012-06-12
申请号：US11207440
申请日：2005-08-19
申请人： Steven J. Burton , Baldev Baines , John Curling , Christopher Bryant , David John Hammond , Dwun-Hou Chen , Timothy Keith Hayes
发明人： Steven J. Burton , Baldev Baines , John Curling , Christopher Bryant , David John Hammond , Dwun-Hou Chen , Timothy Keith Hayes
IPC分类号： A61K38/00 , C12N5/07 , C12P21/04
CPC分类号： C07K14/745 , C07K1/22 , C07K14/775
摘要： The invention discloses methods for sequential protein isolation and purification from a biological sample by affinity chromatography. Affinity chromatography is conducted using ligands or ligand support complexes that selectively and specifically bind to proteins in the biological sample. The ligands or ligand support complexes were contacted sequentially in a predetermined order with the biological sample to allow each ligand or ligand-support complex to sequentially bind a protein from the biological sample.
摘要翻译：本发明公开了通过亲和层析从生物样品中顺序分离和纯化蛋白质的方法。使用选择性且特异性结合生物样品中的蛋白质的配体或配体载体复合物进行亲和层析。配体或配体支持复合物以预定的顺序与生物样品顺序接触，以允许每个配体或配体支持复合物依次结合来自生物样品的蛋白质。

2. 发明申请

US20080160501A1 Plasma protein-binding ligands 审中-公开
标题翻译：血浆蛋白结合配体
公开(公告)号：US20080160501A1
公开(公告)日：2008-07-03
申请号：US11797318
申请日：2007-05-02
申请人： David J. Hammond , Serguei Soukharev
发明人： David J. Hammond , Serguei Soukharev
IPC分类号： C12Q1/00
CPC分类号： G01N33/54306 , C07K1/047 , C07K1/14 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/1008 , C07K7/06 , G01N33/54313 , G01N33/54386 , Y02P20/582
摘要： The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to α1 proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequence provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa4-Xaa5-Xaa5, an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.
摘要翻译：本发明提供了结合至少一种血浆蛋白的分离或纯化的肽。在一个实施方案中，分离或纯化的肽结合纤维蛋白原，包含不超过10个氨基酸，并且包含氨基酸序列Xaa 1 -Xaa 2 -Xaa＆lt; SUB 3个-Xaa 4个-Xaa 5，和氨基酸序列Gly-Xaa 6 -Arg-Xaa 7 或选自本文提供的特定氨基酸序列的氨基酸序列。或者，分离或纯化的蛋白质结合α1蛋白酶抑制剂和/或包含Apo-A1脂蛋白和对氧磷酶的蛋白质复合物。肽包含不超过10个氨基酸，并且包含氨基酸序列Xaa 8 -Xaa 1-His-Xaa 1 -Xaa＆lt; SUB > 3个氨基酸序列和氨基酸序列His-Xaa 8 或者选自本文提供的特定氨基酸序列的氨基酸序列。此外，本发明提供了与血管性血友病因子结合的分离或纯化的肽。肽包含氨基酸序列Xaa 4 -Xaa 5 -Xaa 5 N，氨基酸序列Tyr-Leu-Xaa 11 或者选自本文提供的特定氨基酸序列的氨基酸序列。

3. 发明申请

US20070225226A1 C-REACTIVE PROTEIN APHERESIS 审中-公开
标题翻译： C-反应性蛋白质
公开(公告)号：US20070225226A1
公开(公告)日：2007-09-27
申请号：US11690318
申请日：2007-03-23
申请人： David Hammond , Julie Lathrop
发明人： David Hammond , Julie Lathrop
IPC分类号： A61K38/16 , A61K38/10 , A61K38/08 , A61K38/06 , A61K38/05 , C07K14/16 , C07K7/08 , C07K7/06
CPC分类号： A61K38/08 , A61M1/3486 , A61M1/3679 , C07K7/06
摘要： The present invention provides ligands that can bind CRP with high affinity and high specificity. The present invention also provides a method of treating a condition of elevated CRP through apheresis, by reducing CRP level via its binding to a CRP-specific ligand ex vivo. Systems of performing apheresis to reduce CRP levels are also provided.
摘要翻译：本发明提供可以高亲和力和高特异性结合CRP的配体。本发明还提供了一种通过分离术来治疗CRP升高的病症的方法，通过其离体结合到CRP特异性配体来降低CRP水平。还提供了进行单采血药浓度降低CRP水平的系统。

4. 发明授权

US6117425A Supplemented and unsupplemented tissue sealants, method of their production and use 失效
标题翻译：补充和未补充的组织密封剂，其生产和使用方法
公开(公告)号：US6117425A
公开(公告)日：2000-09-12
申请号：US474086
申请日：1995-06-07
申请人： Martin James MacPhee , William Nash Drohan , Gene Liau , Christian Haudenschild
发明人： Martin James MacPhee , William Nash Drohan , Gene Liau , Christian Haudenschild
IPC分类号： A61K38/17 , A61K38/18 , A61K38/36 , A61K47/42 , A61L15/32 , A61L24/00 , A61L24/10 , A61L26/00 , A61L27/34 , A61L27/50 , C07K14/50 , C12N5/00 , C12N5/071 , A61K38/48 , A61K9/70 , A61L15/16
CPC分类号： A61K38/1841 , A61K38/18 , A61K38/1875 , A61K38/363 , A61K38/45 , A61K38/4833 , A61K47/42 , A61L15/32 , A61L24/0015 , A61L24/106 , A61L26/0042 , A61L26/0052 , A61L26/0066 , A61L26/0085 , A61L27/34 , A61L27/507 , C07K14/501 , C07K14/503 , C12N5/0062 , C12N5/069 , A61K38/00 , A61L2300/256 , A61L2300/402 , A61L2300/404 , A61L2300/414 , A61L2300/416 , A61L2300/418 , A61L2300/602 , C12N2533/56
摘要： This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
摘要翻译：本发明提供补充的组织密封剂，其生产方法及其用途。公开了补充有至少一种细胞毒素或细胞增殖抑制组合物的组织密封剂。该组合物可以进一步补充有例如一种或多种抗体，止痛剂，抗凝剂，抗炎化合物，抗微生物组合物，细胞因子，药物，生长因子，干扰素，激素，脂质，软化骨或骨形态发生蛋白，软骨诱导因子，寡核苷酸聚合物，多糖，多肽，蛋白酶抑制剂，血管收缩剂或血管扩张剂，维生素，矿物质，稳定剂等。

5. 发明授权

US6054122A Supplemented and unsupplemented tissue sealants, methods of their production and use 失效
标题翻译：补充和未补充的组织密封剂，其生产和使用的方法
公开(公告)号：US6054122A
公开(公告)日：2000-04-25
申请号：US479034
申请日：1995-06-07
申请人： Martin James MacPhee , William Nash Drohan , Christoper J. Woolverton
发明人： Martin James MacPhee , William Nash Drohan , Christoper J. Woolverton
IPC分类号： A61K38/17 , A61K38/18 , A61K38/36 , A61K47/42 , A61L15/32 , A61L24/00 , A61L24/10 , A61L26/00 , A61L27/34 , A61L27/50 , C07K14/50 , C12N5/00 , C12N5/071 , A61K34/14 , A61K38/22 , A61K38/44 , A61K38/49
CPC分类号： A61K38/1841 , A61K38/18 , A61K38/1875 , A61K38/363 , A61K38/45 , A61K38/4833 , A61K45/06 , A61K47/42 , A61K9/0024 , A61L15/32 , A61L24/0015 , A61L24/106 , A61L26/0042 , A61L26/0052 , A61L26/0066 , A61L26/0085 , A61L27/34 , A61L27/507 , C07K14/501 , C07K14/503 , C12N5/0062 , C12N5/069 , A61K38/00 , A61K47/46 , A61L2300/256 , A61L2300/402 , A61L2300/404 , A61L2300/414 , A61L2300/416 , A61L2300/418 , A61L2300/602 , C12N2533/56
摘要： This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.
摘要翻译：本发明提供一种纤维蛋白密封剂敷料，其中所述纤维蛋白封闭剂可补充至少一种选自例如一种或多种调节化合物，抗体，抗微生物组合物，止痛剂，抗凝剂，抗增殖剂，抗炎化合物，细胞因子，细胞毒素，药物，生长因子，干扰素，激素，脂质，软化骨或骨形态发生蛋白，软骨诱导因子，寡核苷酸聚合物，多糖，多肽，蛋白酶抑制剂，血管收缩剂或血管扩张剂，维生素，矿物质，稳定剂等。还公开了制备和/或使用未补充或补充的纤维蛋白密封剂敷料的方法。

6. 发明授权

US5723282A Method of preparing organs for vitrification 失效
标题翻译：玻璃化器官的制备方法
公开(公告)号：US5723282A
公开(公告)日：1998-03-03
申请号：US292001
申请日：1994-08-18
申请人： Gregory M. Fahy , Bijan Khirabadi , Yasumitsu Okouchi , Thomas Maciag
发明人： Gregory M. Fahy , Bijan Khirabadi , Yasumitsu Okouchi , Thomas Maciag
IPC分类号： A01N1/02
CPC分类号： A01N1/0247 , A01N1/02 , A01N1/0221
摘要： The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor .beta.1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor .beta.1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.), medium (such as agents with intermediate molecular weights of around 600-2,000) and high (such as hydroxyethyl starch) molecular weight agents osmotic buffering agents. The invention is also directed to new post-transplantation treatments such as the use of transforming growth factor .beta.1, N-acetylcysteine and aurothioglucose. Further, the invention relates to a method of vitrification of organs comprising a multi-step method of introducing increasing concentrations of cryoprotectant with osmotic equilibration of the organ and decreases in temperature prior to perfusion with vitrifiable concentrations of cryoprotectant at about -5.degree. C. to -35.degree. C.
摘要翻译：本发明涉及器官和组织灌注领域。更具体地，本发明涉及通过向其中引入可玻璃化浓度的冷冻保护剂来制备用于冷冻保存的器官如肾脏和肝脏的方法。为了制备用于低温保存的器官，供体人或动物以常规方式治疗，并且还可以用伊洛前列素或其它血管扩张剂和/或转化生长因子β1治疗。或者或另外，可以冷冻保存伊洛前列素或其他血管扩张剂，和/或将生长因子β1直接转化到其动脉中。本发明还涉及通过使用低（例如棉子糖，蔗糖，甘露醇等）的培养基（例如具有约600-2,000中等分子量的试剂）从其中除去冷冻保护剂的方法来制备用于移植的器官和高（如羟乙基淀粉）分子量试剂渗透缓冲剂。本发明还涉及新的移植后治疗，例如使用转化生长因子β1，N-乙酰半胱氨酸和嘌呤硫代葡萄糖。此外，本发明涉及一种器官玻璃化方法，其包括多步骤方法，其在器官的渗透平衡下引入增加浓度的冷冻保护剂，并在灌注之前温度降低，在约-5℃至可冷冻浓度的冷冻保护剂至 -35℃

7. 外观设计

USD759249S1 Electronic device 有权
公开(公告)号：USD759249S1
公开(公告)日：2016-06-14
申请号：US29507779
申请日：2014-10-30
申请人： The American National Red Cross
设计人： John L. Beales

8. 发明申请

US20100255521A1 Fluorescent substrates for Detecting organophosphatase enzyme activity 审中-公开
标题翻译：荧光底物用于检测有机磷酸酶活性
公开(公告)号：US20100255521A1
公开(公告)日：2010-10-07
申请号：US11648679
申请日：2007-01-03
申请人： Serguei Soukharev , David Hammond
发明人： Serguei Soukharev , David Hammond
IPC分类号： C12Q1/42 , C07F9/12
CPC分类号： C07F9/65522 , C07F9/6561 , C12Q1/42
摘要： Disclosed are compounds of the formula (I): wherein R3, R4, R5, R9, and R10 are selected from the group consisting of H and groups or atoms other than H, and R6 and R8 are halo or hydrogen; X1, X2, and X3 are independently O or S; provided that R9 and R10 are not simultaneously H, when all of X1, X2, and X3 are O; and of the formula (II) wherein R11-R14 are selected from the group consisting of H and groups or atoms other than H; X4-X9 are independently O or S; n and m are 0 or 1 but m and n cannot be 0 simultaneously; R15-R24 can be H or any substituent so long as the compound of formula II upon hydrolysis provides a fluorescent compound. These compounds are useful as substrates with high specificity for organophosphatase particularly human paraoxonase and bacterial organophosphorus hydrolase. Also disclosed is a method for detecting and/or measuring the paraoxonase activity in a fluid comprising contacting the fluid with a fluorescent substrate and measuring the fluorescence of the fluorescent product formed.
摘要翻译：公开了式（I）的化合物：其中R 3，R 4，R 5，R 9和R 10选自H和H以外的基团或原子，R 6和R 8是卤素或氢; X1，X2和X3独立地为O或S; 条件是当X1，X2和X3全部为O时，R9和R10不同时为H; 和式（II）的化合物，其中R11-R14选自H和H以外的基团或原子; X4-X9独立地为O或S; n和m是0或1，但m和n不能同时为0; R15-R24可以是H或任何取代基，只要在水解时式II化合物提供荧光化合物即可。这些化合物可用作对有机磷酸酶特别是人类对氧磷酶和细菌有机磷水解酶具有高特异性的底物。还公开了一种用于检测和/或测量流体中对氧磷酶活性的方法，包括使流体与荧光底物接触并测量形成的荧光产物的荧光。

9. 发明申请

US20090258834A1 Plasma protein-binding ligands 审中-公开
标题翻译：血浆蛋白结合配体
公开(公告)号：US20090258834A1
公开(公告)日：2009-10-15
申请号：US11802730
申请日：2007-05-24
申请人： David J. Hammond , Julia Tait Lathrop , Annemarie Ralston , Timothy K. Hayes , Iwona Fijalkowska
发明人： David J. Hammond , Julia Tait Lathrop , Annemarie Ralston , Timothy K. Hayes , Iwona Fijalkowska
IPC分类号： A61K38/06 , G01N33/573 , C12N9/14 , G01N33/566 , C07K7/06 , A61K38/08 , C07K5/08 , C07K14/435 , C07K14/75 , C07K14/575
CPC分类号： G01N33/54306 , C07K1/047 , C07K1/14 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/1008 , C07K7/06 , G01N33/54313 , G01N33/54386 , Y02P20/582
摘要： The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to α1 proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa4-Xaa5-Xaa5, an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.
摘要翻译：本发明提供了结合至少一种血浆蛋白的分离或纯化的肽。在一个实施方案中，分离或纯化的肽结合纤维蛋白原，包含不超过10个氨基酸，并且包含氨基酸序列Xaa1-Xaa2-Xaa3-Xaa4-Xaa5，氨基酸序列Gly-Xaa6-Arg-Xaa7或选自本文提供的特定氨基酸序列的氨基酸序列。或者，分离或纯化的蛋白质结合α1蛋白酶抑制剂和/或包含Apo-A1脂蛋白和对氧磷酶的蛋白质复合物。该肽包含不超过10个氨基酸并且包含氨基酸序列Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3和氨基酸序列His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2或选自本文提供的特异性氨基酸序列。此外，本发明提供了与血管性血友病因子结合的分离或纯化的肽。肽包含氨基酸序列Xaa4-Xaa5-Xaa5，氨基酸序列Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr或选自本文提供的特定氨基酸序列的氨基酸序列。

10. 发明授权

US07223734B2 Plasma protein-binding ligands 失效
标题翻译：血浆蛋白结合配体
公开(公告)号：US07223734B2
公开(公告)日：2007-05-29
申请号：US10414524
申请日：2003-04-14
申请人： David J. Hammond , Julia Tait Lathrop , Iwona Fijalkowska
发明人： David J. Hammond , Julia Tait Lathrop , Iwona Fijalkowska
IPC分类号： A61K38/08 , C07K7/04 , C07K2/00
CPC分类号： G01N33/54306 , C07K1/047 , C07K1/14 , C07K5/0812 , C07K5/0815 , C07K5/0821 , C07K5/1008 , C07K7/06 , G01N33/54313 , G01N33/54386 , Y02P20/582
摘要： The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to αl proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa4-Xaa5-Xaa5, an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.
摘要翻译：本发明提供了结合至少一种血浆蛋白的分离或纯化的肽。在一个实施方案中，分离或纯化的肽结合纤维蛋白原，包含不超过10个氨基酸，并且包含氨基酸序列Xaa 1 -Xaa 2 -Xaa＆lt; SUB 氨基酸序列Gly-Xaa 6 -Arg-Xaa 7（SEQ ID NO：3）或选自本文提供的特定氨基酸序列的氨基酸序列。或者，分离或纯化的蛋白质结合到α1-蛋白酶抑制剂和/或包含Apo-A1脂蛋白和对氧磷酶的蛋白质复合物。该肽包含不超过10个氨基酸，并且包含氨基酸序列Xaa 8 -Xaa 8 -Xaa 1-His-Xaa _{1个-Xaa 3个氨基酸序列，并且氨基酸序列His-Xaa 8 -Xaa 9 -Xaa 1}

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式